Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18058612 | 0.85 | DAO (0.46) | MTNR1AMTNR1BKMT2AMCL1ALDH1A1 | |
| SCHEMBL31070155 | 0.83 | KDM4E (0.46) | KMT2AMCL1L3MBTL1ALDH1A1KDM4E | |
| SCHEMBL1585615 | 0.83 | NOD2 (0.60) | MTNR1AMTNR1BKMT2AMCL1L3MBTL1 | |
| SCHEMBL7884242 | 0.81 | DAO (0.64) | MTNR1AMTNR1BKMT2AMCL1L3MBTL1 | |
| SCHEMBL4740170 | 0.81 | MTNR1A (0.53) | MTNR1AMTNR1BKMT2AMCL1L3MBTL1 | |
| SCHEMBL4486403 | 0.81 | L3MBTL1 (0.67) | MTNR1AMTNR1BKMT2AMCL1L3MBTL1 | |
| SCHEMBL29834903 | 0.81 | L3MBTL1 (0.67) | MTNR1AMTNR1BKMT2AMCL1L3MBTL1 | |
| SCHEMBL7873282 | 0.80 | MTNR1A (0.56) | MTNR1AMTNR1BKMT2AMCL1L3MBTL1 | |
| SCHEMBL2662561 | 0.80 | MCL1 (0.47) | KMT2AMCL1ALDH1A1KDM4EDAO | |
| SCHEMBL27770675 | 0.80 | MTNR1A (0.52) | MTNR1AMTNR1BKMT2AMCL1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118515601-A | Preparation method of anti-tumor isoindolinone compound | 华东理工大学 | 2024-08-20 | — | — | CN | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-20090214529-A9 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-08-27 | — | — | US | disclosed |
| US-20090214529-A9 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-08-27 | — | — | US | disclosed |
| US-20090214529-A9 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2009-08-27 | — | — | US | disclosed |
| WO-2008147852-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-12-04 | — | — | WO | disclosed |
| US-20080292626-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-11-27 | — | — | US | disclosed |
| US-20080292626-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-11-27 | — | — | US | disclosed |
| US-20080292626-A1 | KINESIN INHIBITORS | TAIGEN BIOTECHNOLOGY CO., LTD. (TW) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214529-A9 | KINESIN INHIBITORS | KIF5B, KIF5A, KIF5C | MTNR1A 4358/4885MTNR1B 4163/4885KMT2A 1540/4885 |
| US-20080292626-A1 | KINESIN INHIBITORS | KIF5B, KIF5A, KIF5C | MTNR1A 4358/4885MTNR1B 4163/4885KMT2A 1540/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | MTNR1A 3659/4885MTNR1B 2704/4885KMT2A 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.